Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

28 Oct 2022

Numinus Launches Ketamine Program for Chronic and Serious Illness

Numinus launches Ketamine for Chronic and Serious Medical Illness Program....

By Microdose NewsDesk

Don’t Miss

27 Oct 2022

News You Might Have Missed: Oct 27th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

26 Oct 2022

Atai Completes Enrollment of Phase 2a Trial for Depression

atai’s subsidiary, has completed enrollment of Phase 2a double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine) for treatment-resistant depression....

By Microdose NewsDesk

Industry

24 Oct 2022

Algernon Partners with Yale University for DMT Phase 2 Depression Trial

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

19 Oct 2022

Small Pharma Expands IP With Another US Patent

This is the second United States Patent granted for Small Pharma’s psychedelics portfolio...

By Microdose NewsDesk

Don’t Miss

17 Oct 2022

News You Might Have Missed: Oct 17th, 2022

come to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Finance

13 Oct 2022

Palo Santo Closes $50 Million Psychedelic Investment Fund

Palo Santo announced the closing of its $50 million fund....

By Microdose NewsDesk

Industry

12 Oct 2022

Atai Announces Positive Phase 1 Results for Opioid Use Disorder

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD...

By Microdose NewsDesk

Industry

12 Oct 2022

Convergence Partners Invests in Psychedelic CRO Clerkenwell Health

Convergence Partners is investing in the transformational psychedelic medicines sector by participating in the seed investment round of Clerkenwell Health Ltd....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.